Cilag

SiO2 Materials Science Names Yves Steffen as Chief Executive Officer

Retrieved on: 
Thursday, September 1, 2022
University of California, Santa Barbara, University, CEO, Research, Innovation, Board, Drug packaging, Materials science, MIT, Lead, GLOBE, Silicon dioxide, Director, Customer satisfaction, Chicago (franchise), Growth, Industry, Cilag, Fine chemical, Management, Novartis, Science

AUBURN, Ala., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SiO2 Materials Science today announced the Board of Directors has appointed Yves Steffen as CEO effective Aug. 1, 2022.

Key Points: 
  • AUBURN, Ala., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SiO2 Materials Science today announced the Board of Directors has appointed Yves Steffen as CEO effective Aug. 1, 2022.
  • Yves Steffen is a graduate of FHBB and has more than 20 years of experience in the pharmaceutical industry in various positions.
  • Robert Abrams,Chairman of the SiO2 Board, said, "In recent years, SiO2 has successfully completed the development of a revolutionary technology for the life science industry.
  • SiO2 Materials Science is an advanced materials science corporation introducing breakthrough disruptive technology serving the biopharma, molecular diagnostic, and consumer healthcare industries.

 Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

Retrieved on: 
Saturday, June 12, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Drugs, Health care, Health sciences, Orphan drugs, Daratumumab, Multiple myeloma, Lenalidomide, Bortezomib, Dexamethasone, Janssen Pharmaceuticals, Cilag, Immunomodulatory imide drug, the MAIA Trial, daratumumab, Multiple Myeloma, the Janssen Pharmaceutical Companies of Johnson & Johnson, THE MAIA TRIAL, DARATUMUMAB, MULTIPLE MYELOMA, THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma.

Key Points: 
  • These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma.
  • Janssen Research & Development, LLC, Janssen-Cilag Ltd., Janssen Pharmaceutica NV and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Overall Survival Results With Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Transplant-ineligible Newly Diagnosed Multiple Myeloma: Phase 3 MAIA Study.
  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

CDR-Life Appoints Industry Veteran Björn Peters as Chief Business Officer

Retrieved on: 
Wednesday, June 9, 2021
Johnson & Johnson, Companies, Life sciences, Industry economics), Cilag, Movetis, Shire

ZURICH, June 9, 2021 /PRNewswire/ -- CDR-Life Inc ., a biotherapeutics company developing tumor-specific immunotherapies based on a proprietary antibody platform, today announced the expansion of its leadership team with the appointment of Bjrn Peters as chief business officer.

Key Points: 
  • ZURICH, June 9, 2021 /PRNewswire/ -- CDR-Life Inc ., a biotherapeutics company developing tumor-specific immunotherapies based on a proprietary antibody platform, today announced the expansion of its leadership team with the appointment of Bjrn Peters as chief business officer.
  • Prior to joining CDR-Life, Mr. Peters served as head of business development at both Allecra Therapeutics and Zealand Pharma.
  • Earlier in his career, he held positions of increasing responsibility within business development at Shire Pharmaceuticals, Movetis (a spin-off from Johnson & Johnson, subsequently acquired by Shire Pharmaceuticals) and Johnson & Johnson subsidiary, Janssen-Cilag.
  • CDR-Life, a biotherapeutics company, develops novel immunotherapies that target the power of the immune system specifically to tumor cells.

Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

Retrieved on: 
Monday, May 24, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health care, Health sciences, Johnson & Johnson, Health, Protein domains, Orphan drugs, Multiple myeloma, B-cell maturation antigen, Cilag, Janssen Pharmaceuticals, Genmab, Takeda Oncology, Talquetamab, Multiple Myeloma, the Janssen Pharmaceutical Companies of Johnson & Johnson, TALQUETAMAB, MULTIPLE MYELOMA, THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

Patients in this study had progressed, had relapsed after, or were refractory to numerous multiple myeloma therapies.

Key Points: 
  • Patients in this study had progressed, had relapsed after, or were refractory to numerous multiple myeloma therapies.
  • As of April 18, 2021, 184 patients with relapsed or refractory multiple myeloma had received talquetamab.
  • Janssen Pharmaceutica NV, Janssen Research & Development, LLC, and Janssen-Cilag Limited are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Teclistamab and Talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

Emergex Strengthens Senior Management Team

Retrieved on: 
Tuesday, February 23, 2021
Companies, Cilag, Johnson & Johnson, Life sciences, Industry economics)

The Company is also pleased to announce the appointment of Ms Susi Osborne as Manufacturing Director, who joined Emergex in January this year.

Key Points: 
  • The Company is also pleased to announce the appointment of Ms Susi Osborne as Manufacturing Director, who joined Emergex in January this year.
  • Mr Cohen joins Emergex from Janssen-Cilag, a subsidiary of Johnson & Johnson, where, since 2017, he was working as part of the EMEA regional Business Development Team and also responsible for Business Development in the UK pharmaceutical business.
  • Prior to this, he was successful in a number of senior leadership roles in both Sales and Marketing fields across multiple therapy areas.
  • I am looking forward to working with the team at Emergex to advance vaccine candidates with the potential to prevent some of the worlds most deadly infectious diseases.

Janssen to Present Robust Evidence for Solid Tumour Portfolio and Pipeline at 2021 ASCO GU

Retrieved on: 
Wednesday, February 3, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Johnson & Johnson, Health sciences, Health care, Companies, Janssen Pharmaceuticals, Cilag, Janssen, Niraparib, apalutamide, abiraterone acetate, erdafitinib, niraparib, The Janssen Pharmaceutical Companies of Johnson & Johnson

Janssen-Cilag, S.A., Janssen Biotech, Inc. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points: 
  • Janssen-Cilag, S.A., Janssen Biotech, Inc. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.
  • None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
  • Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Retrieved on: 
Monday, December 28, 2020
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Johnson & Johnson, Quinazolines, Companies, Organic compounds, Health, Epidermal growth factor receptor, Oncogenes, Non-small-cell lung carcinoma, Cilag, Janssen Pharmaceutica, Lung cancer, Janssen Biotech, Amivantamab, Non-Small Cell Lung Cancer (NSCLC), the Janssen Pharmaceutical Companies of Johnson & Johnson

Janssen Research & Development, LLC; Janssen-Cilag, S.A. and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points: 
  • Janssen Research & Development, LLC; Janssen-Cilag, S.A. and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
  • Antitumor Activity of Amivantamab (JNJ-61186372), an EGFRMET Bispecific Antibody, in Diverse Models of EGFR Exon 20 InsertionDriven NSCLC.
  • Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.

Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe

Retrieved on: 
Monday, December 21, 2020
Biotechnology, Infectious diseases, AIDS, Health, Pharmaceutical, Johnson & Johnson, Companies, Health sciences, Health care, Janssen Pharmaceutica, ViiV Healthcare, Cilag, Janssen, Cabotegravir, HIV

There has been significant progress in the way HIV is managed and perceived over the past 30 years.

Key Points: 
  • There has been significant progress in the way HIV is managed and perceived over the past 30 years.
  • Cabotegravir is an INI developed by ViiV Healthcare for the treatment of HIV-1 in virologically suppressed adults.
  • This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection.
  • Janssen-Cilag International NV, Janssen Research & Development, LLC and Janssen Sciences Ireland Unlimited Company are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Janssen Receives Positive CHMP Opinion for SPRAVATO®▼ (Esketamine Nasal Spray) for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder

Retrieved on: 
Friday, December 11, 2020
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Mental health, Clinical trials, Other Health, Drugs, Psychoactive drugs, Health sciences, Amines, Chloroarenes, Nicotinic antagonists, Sedatives, Janssen Pharmaceutica, Esketamine, Johnson & Johnson, Cilag, Nasal spray, esketamine nasal spray, Major Depressive Disorder, the Janssen Pharmaceutical Companies of Johnson & Johnson

If approved by the European Commission, esketamine nasal spray has the potential to offer individuals relief from debilitating depressive symptoms and address a key unmet need within this population.

Key Points: 
  • If approved by the European Commission, esketamine nasal spray has the potential to offer individuals relief from debilitating depressive symptoms and address a key unmet need within this population.
  • The European Commission has the authority to grant marketing authorisation for medicines in the European Economic Area.
  • Janssen Research & Development, LLC and Janssen-Cilag International NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding SPRAVATO (esketamine nasal spray).

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma

Retrieved on: 
Saturday, December 5, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Health care, Health sciences, Johnson & Johnson, Gene therapy, B-cell maturation antigen, Cilag, Chimeric antigen receptor T cell, Multiple myeloma, Janssen Pharmaceutica, Genmab, Takeda Oncology

In the CARTITUDE-1 study, heavily pretreated patients, including those who were triple-class refractory, achieved an impressive response following a single infusion of ciltacabtagene autoleucel.

Key Points: 
  • In the CARTITUDE-1 study, heavily pretreated patients, including those who were triple-class refractory, achieved an impressive response following a single infusion of ciltacabtagene autoleucel.
  • Janssen-Cilag Ltd., Middle East and Janssen Research and Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of ciltacabtagene autoleucel.
  • Cartitude-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation AntigenDirected Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma.